Uva-dare (digital Academic Repository) Differential Effects of Enzyme Supplementation Therapy on Manifestations of Type 1 Gaucher Disease Differential Effects of Enzyme Supplementation Therapy on Manifestations of Type 1 Gaucher Disease

General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: BACKGROUND: In type 1 Gaucher disease (GD), the accumulation of glucocerebroside in macrophages, caused by deficient activity of glucocerebrosidase, results in a variety of disease manifestations. In addition to the characteristic features of hepatosplenomegaly, cytopenia, and bone abnormalities, resting energy expenditure (REE) and glucose production are increased. In this study the effects of enzyme supplementation therapy on metabolic parameters in relation to other disease manifestations in type 1 GD patients are investigated. PATIENTS AND METHODS: In 12 adult type 1 GD patients, measurements of REE (by indirect calorimetry), liver and spleen volume (by spiral computerized axial tomography [CT]) and hemoglobin and platelet count were obtained before and after 6 months of alglucerase therapy (15 U/kg per month). In 7 of the 12 patients hepatic glucose production was measured by infusing 3-3 H glucose. For comparison, REE and glucose metabolism were studied in 7 weight-and age-matched healthy subjects. RESULTS: REE and glucose production were increased in GD patients as compared with controls (REE: 29.8 kcal/kg/24 h { 3.6 and 23.1 { 2.3 kcal/kg/24 h, respectively, P õ 0.05; glucose production: 14.00 mmol/kg/min { 0.51 and 10.77 mmol/kg/min { 0.26, respectively, P õ 0.03). There were no differences in plasma glucose concentrations. Whereas the elevated REE decreased after 6 months of alglucerase therapy from 129% to 120% of predicted values (P õ 0.01), the increase in hepatic glucose production did not

[1]  J. Romijn,et al.  Increased basal glucose production in type 1 Gaucher's disease. , 1995, The Journal of clinical endocrinology and metabolism.

[2]  M. Horowitz,et al.  Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. , 1994, The American journal of medicine.

[3]  C. Hollak,et al.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. , 1994, The Journal of clinical investigation.

[4]  E. Levy-Lahad,et al.  Low‐dose high‐frequency enzyme replacement therapy for very young children with severe Gaucher disease , 1993, British journal of haematology.

[5]  J. Koziol,et al.  A less costly regimen of alglucerase to treat Gaucher's disease. , 1992, The New England journal of medicine.

[6]  A. Saven,et al.  Gaucher Disease: Clinical, Laboratory, Radiologic, and Genetic Features of 53 Patients , 1992 .

[7]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[8]  J. Romijn,et al.  Decreased glucose oxidation during short-term starvation. , 1990, Metabolism: clinical and experimental.

[9]  N. LeLeiko,et al.  Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements. , 1989, Metabolism: clinical and experimental.

[10]  J. Kamps,et al.  Cellular communication inside the liver. Binding, conversion and metabolic effect of prostaglandin D2 on parenchymal liver cells. , 1989, The Biochemical journal.

[11]  J. Barranger,et al.  Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[12]  R. Brady,et al.  Selective effects of glucocerebroside (Gaucher's storage material) on macrophage cultures. , 1981, The Journal of clinical investigation.

[13]  S. Heymsfield,et al.  Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. , 1979, Annals of internal medicine.

[14]  J. Tobin,et al.  Effects of arterial versus venous sampling on analysis of glucose kinetics in man. , 1976, Journal of applied physiology.

[15]  A. George.  The metabolic basis of inherited disease , 1961 .

[16]  C. Steer,et al.  Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. , 1981, Biochimica et biophysica acta.